Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Glioblastoma 4Oligodendroglioma 3Gliosarcoma 3Glioma 3Brain Neoplasms 3Astrocytoma 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Supratentorial Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × lonafarnib × Clear all
NCT00020774 2020-07-31

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡